1. Center for the Study of Myelofibrosis, Biotechnology Research Area, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy;
2. Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ;
3. Division of Hematology and Research Foundation, Ospedale Papa Giovanni XXIII, Bergamo, Italy;
4. Department of Haematology, St Thomas Hospital, London, United Kingdom;
5. Saint-Louis Hospital and Paris Diderot University, Paris, France;
6. Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany;
7. Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, United Kingdom;
8. Division of Hematology, Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, Varese, Italy;
9. University of Florence, Florence, Italy;
10. Department of Hematology, Institut Hospital del Mar d'Investigations Mediques, Barcelona, Spain;
11. University of Vienna, Department of Internal Medicine, Wien, Austria;
12. Department of Internal Medicine, Karolinska Institute at Stockholm South Hospital, Stockholm, Sweden;
13. MD Anderson Cancer Center, Houston, TX;
14. Division of Hematology/Oncology, Pathology and Surgery, Tisch Cancer Institute, Myeloproliferative Disorders Research Consortium, Mount Sinai School of Medicine, New York, NY;
15. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN; and
16. University of Barcelona, Hospital Clínic, Hematology Department, Institut D’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain